Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Nektar Therapeutics (NKTR)

Nektar Therapeutics (NKTR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,477,978
  • Shares Outstanding, K 175,922
  • Annual Sales, $ 1,193 M
  • Annual Income, $ 681,310 K
  • 60-Month Beta 2.60
  • Price/Sales 28.92
  • Price/Cash Flow 5.28
  • Price/Book 2.49

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.69
  • Number of Estimates 8
  • High Estimate -0.56
  • Low Estimate -0.75
  • Prior Year -0.57
  • Growth Rate Est. (year over year) -21.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.67 +0.51%
on 01/27/20
28.60 -30.87%
on 01/13/20
-1.80 (-8.34%)
since 12/27/19
3-Month
16.68 +18.53%
on 10/31/19
28.60 -30.87%
on 01/13/20
+3.09 (+18.53%)
since 10/25/19
52-Week
15.64 +26.45%
on 10/15/19
47.11 -58.03%
on 02/11/19
-24.15 (-54.99%)
since 01/25/19

Most Recent Stories

More News
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR

Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com...

NKTR : 19.77 (-6.44%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR

Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com...

NKTR : 19.77 (-6.44%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR

Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com...

NKTR : 19.77 (-6.44%)
Nektar's Pain Drug Gets Adverse Advisory Committee Decision

Nektar (NKTR) to stop development of chronic pain candidate, NKTR-181, following two FDA advisory committees' decision to not recommend its approval.

LLY : 138.31 (-0.55%)
BMY : 63.70 (-0.72%)
GILD : 63.83 (+1.08%)
NKTR : 19.77 (-6.44%)
Nektar Issues Statement Regarding FDA Advisory Committee Vote for Oxycodegol

Nektar Therapeutics (NASDAQ: NKTR) issued a statement today following a meeting of the Food and Drug Administration's (FDA's) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) and Drug...

NKTR : 19.77 (-6.44%)
25.5% Return Seen to Date on SmarTrend Nektar Therapeut Call (NKTR)

SmarTrend identified an Uptrend for Nektar Therapeut (NASDAQ:NKTR) on November 11th, 2019 at $21.40. In approximately 2 months, Nektar Therapeut has returned 25.49% as of today's recent price of $26.86....

NKTR : 19.77 (-6.44%)
Thinking about buying stock in Bilibili, Microsoft, Nio, Nektar Therapeutics, or NVIDIA?

InvestorsObserver issues critical PriceWatch Alerts for BILI, MSFT, NIO, NKTR, and NVDA.

BILI : 22.30 (+2.20%)
MSFT : 162.28 (-1.67%)
NKTR : 19.77 (-6.44%)
NIO : 4.01 (-13.95%)
NVDA : 240.20 (-4.10%)
Nektar Up 25% as Bristol-Myers Expands Bempeg Collaboration

Nektar (NKTR) agrees to a new joint development plan with Bristol-Myers to include two new registrational studies to evaluate bempegaldesleukin plus Opdivo in bladder cancer and adjuvant melanoma.

BMY : 63.70 (-0.72%)
MRK : 86.10 (+0.14%)
PFE : 40.16 (+0.85%)
NKTR : 19.77 (-6.44%)
Shareholder Alert: Robbins LLP Reminds Investors Nektar Therapeutics (NKTR) Sued for Misleading Shareholders

Shareholder rights law firm Robbins LLP reminds investors that purchasers of Nektar Therapeutics (NASDAQ: NKTR) filed a derivative complaint against the company's officers and directors for alleged breaches...

NKTR : 19.77 (-6.44%)
Watch for Nektar Therapeut to Potentially Pullback After Gaining 11.42% Yesterday

Nektar Therapeut (NASDAQ:NKTR) traded in a range yesterday that spanned from a low of $22.50 to a high of $24.36. Yesterday, the shares gained 11.4%, which took the trading range above the 3-day high...

NKTR : 19.77 (-6.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade NKTR with:

Business Summary

Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to meet unmet medical needs and improve the benefits of drugs for patients. Its product pipeline consists...

See More

Key Turning Points

2nd Resistance Point 20.86
1st Resistance Point 20.32
Last Price 19.77
1st Support Level 19.45
2nd Support Level 19.12

See More

52-Week High 47.11
Fibonacci 61.8% 35.09
Fibonacci 50% 31.37
Fibonacci 38.2% 27.66
Last Price 19.77
52-Week Low 15.64

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar